Anika Therapeutics | ANIK - Gewinn Vor Steuern





Gewinn Vor Steuern Veränderung Datum
Abbott USD 2.39B 27M 2026-03
Agenus USD 39.21M 49.82M 2026-03
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD -178.9M 41.34M 2026-06
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Insmed USD -11.37M 150.72M 2026-06
Integra LifeSciences USD -2.41M 6.72M 2026-03
Intrexon USD -60.48M 27.09M 2024-06
J&J USD 8.66B 839M 2026-06
Karyopharm Therapeutics USD -22.39M 17.51M 2026-03
Ligand Pharmaceuticals USD -24.26M 81.04M 2026-03
MacroGenics USD -36.77M 21.84M 2026-03
Merit Medical Systems USD 53.55M 2.49M 2026-03
Rigel Pharmaceuticals USD -1.03M 7.22M 2024-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sanofi EUR 837M 1.17B 2026-06
Smith & Nephew USD 469M 70M 2025-12
Stryker USD 850M 855M 2026-03
Veracyte USD 26.52M 3.45M 2026-06
Xencor USD -21.92M 106.72M 2026-06
Zimmer Biomet Holdings USD 487.5M 186.2M 2026-06